RestructuringMay 7, 2026, 04:25 PM
Werewolf Therapeutics Faces Going Concern Doubt, Cuts 64% Workforce
AI Summary
Werewolf Therapeutics, Inc. has expressed substantial doubt about its ability to continue as a going concern and initiated a strategic review process to maximize stockholder value. As part of a restructuring plan in February 2026, the company reduced its workforce by 64%. For Q1 2026, the company reported a net loss of $13.5 million, an improvement from $18.1 million in Q1 2025, and ended the quarter with $46.5 million in cash and cash equivalents. The company also repaid its K2HV Loan Agreement on May 6, 2026.
Key Highlights
- Substantial doubt about ability to continue as a going concern.
- Initiated strategic review process to explore alternatives.
- Implemented restructuring plan, reducing workforce by 64%.
- Q1 2026 net loss improved to $13.5 million from $18.1 million YoY.
- Cash and cash equivalents stood at $46.5 million as of March 31, 2026.
- Research and development expenses decreased to $8.2 million from $13.1 million YoY.
- Repaid all obligations under the K2HV Loan Agreement on May 6, 2026.